ECHO Idaho: Behavioral Health in Primary Care

Long Acting Injectables

September 4, 2019

Stephen Carlson, PharmD
Disclosures

• Dr. Carlson has provided consulting services for Alkermes in the past.

• Dr. Carlson has no other financial relationships with commercial interests to disclose.
Learning Objectives

• Describe advantages of utilizing Long Acting Injectables (LAIs)
• Describe difference between lack of hypersensitivity and tolerance of medication
• Understand indications for Second Generation Antipsychotic Agents
What do these indications have in common?

- Ankylosing spondylitis
- Type 2 diabetes mellitus
- Migraine prophylaxis
- Plaque psoriasis
- Endometrial carcinoma
- Crohn’s disease
- Contraception
Advantages of LAIs

• “Life, Death and Recurrence of Schizophrenia symptoms” - Dr. Rakesh Jain

• Schizophrenia and Bipolar Disorder Patients are associated with higher percentage of non-compliance then other common disease states. (1-4)

• Community Benefits(5)
Patient Conversations

• Not reserved for only the worst cases
• Plant the seed
• Don’t avoid due to personal fear of injections
• Fear of the injection (self fulfilling)
• Similar to other classes of medication therapy
• Compliance not punishment
Avoiding an Adverse Reaction

• Verifying appropriate medication by:
  – Establishing a history of taking the oral formulation without anaphylaxis
    --OR--
  – Observing the patient following two separate doses over a minimum of 48hrs without anaphylaxis

• This is considered a lack of hypersensitivity, but is not establishing tolerability.
Initiation Phases

- Lack of hypersensitivity is established
- Goal is to get to steady state
- Each product has specific dosing in an effort to get to steady state as soon as possible
Examples of Initiation

• Day 1 High Dose LAI & stop oral medication, then Day 8(+/− 4 days) Medium Dose LAI, then once every 4 weeks following 2\textsuperscript{nd} injection.

• Day 1 High Dose LAI & continue oral antipsychotic for 14 consecutive days to maintain therapeutic concentrations, then once every 4 weeks following Day 1.
Examples of Initiation

• Day 1 High/Med/Low Dose LAI with 3 hr post injection monitoring every 2 weeks for 2 doses, then every 4 weeks (REMS reporting and training required)

• Day 1 High Dose Oral, Initiation Injectable and Med Dose LAI, then every 4 – 8 weeks (additional oral doses not required)
Indications

• Treatment of Schizophrenia
  – ZyPREXA Relprevv
  – Aristada (Aristada Initio*)
  – Invega Sustenna and Invega Trinza
  – Abilify Maintena

• Treatment of Bipolar I disorder
  – Abilify Maintena

*The 675 mg strength aripiprazole lauroxil (Aristada Initio) is only to be used as a single-dose in combination with oral aripiprazole for initiation of long-term treatment with aripiprazole lauroxil (Aristada) or as a single dose to reinitiate treatment after a missed dose of aripiprazole lauroxil (Aristada). It is not intended for repeat dosing.
Take Home Points

• Difference between hypersensitivity and tolerability

• Schizophrenic patients have a history of not being compliant on oral medications
References